An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease

Heart Int. 2021 Dec 10;15(2):73-78. doi: 10.17925/HI.2021.15.2.73. eCollection 2021.

Abstract

For the treatment of peripheral arterial disease, drug-eluting technology is a widely accepted therapeutic option, with significant reduction in intimal hyperplasia and, consequently, use of target lesion revascularization. Nevertheless, the reputation of such devices was damaged after a meta-analysis, published in December 2018, showed increased mortality in patients receiving paclitaxel-eluting devices. Although subsequent studies have failed to establish such correlation, the use of paclitaxel-eluting devices remains heavily restricted. As such, other options and drugs have been developed, for instance sirolimus. In this article we present the available data on drug-eluting technology.

Keywords: Paclitaxel; drug-coated balloon; drug-eluting stents; drug-eluting technology; peripheral arterial disease; sirolimus.

Publication types

  • Review

Grants and funding

Support: No funding was received in the publication of this article.